Roche's Tecentriq (atezolizumab) Receives Health Canada's Approval for 1L Extensive-Stage Small Cell Lung Cancer in Adults
Shots:
- The approval is based on P-III IMpower133 study results assessing Tecentriq + carboplatin and etoposide vs carboplatin and etoposide monothx in 403 adults with chemotherapy-naïve ES-SCLC
- P-III IMpower133 study results: mOS (12.3 mos. vs 10.3 mos.)- mPFS (5.2 mos. vs 4.3 mos.) 30% reduction in death- OS @1 year (51.7% vs. 38.2%). The regimen is included as a preferred treatment for previously untreated ES-SCLC in the 2019 NCCN Clinical Practice Guidelines in Oncology for SCLC
- Tecentriq (atezolizumab) is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptor and novel therapy approved in Canada for SCLC and is being evaluated in 12 P-III trials as monothx or in combination with other drugs
Click here to read full press release/ article
Ref: Roche | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com